1Z2MAP1O, also known as 1-(indolizin-3-yl)-2-(methylamino)propan-1-one, is a monoamine releasing agent and serotonin receptor modulator of the indolizinylethylamine family. It is an analogue of BK-NM-AMT (β-keto-N-methyl-α-methyltryptamine) in which the indole ring has been replaced with an indolizine ring.

1Z2MAP1O has been found to be a serotonin and dopamine releasing agent as well as a weak serotonin 5-HT_1B receptor agonist and serotonin 5-HT_2B receptor antagonist. Conversely, its activity as a norepinephrine releasing agent was not reported, and it was inactive at the remaining sites of the 47 screened targets. The drug's EC₅₀Tooltip half-maximal effective concentration values for induction of monoamine release were 109 nM for serotonin and 227 nM for dopamine in Chinese hamster ovary (CHO) cells expressing the human monoamine transporters (MATs). The dopamine/serotonin ratio was 0.48. Its EC₅₀ at the serotonin 5-HT_1B receptor was 1,130 nM, whereas its IC₅₀Tooltip half-maximal inhibitory concentration values were 2,140 nM at the serotonin 5-HT_2B receptor, 2,410 nM at the dopamine transporter (DAT), and 5,690 nM at the norepinephrine transporter (NET). 1Z2MAP1O's inhibition of the serotonin transporter (SERT) was not reported.

1Z2MAP1O was patented by Matthew Baggott of Tactogen in 2023.